Molecular Classification Predicts Clinical Outcomes of Kidney Transplant Recipients With Microvascular Inflammation, Donor-specific Antibodies-negative and C4d-negative
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Microvascular inflammation (MVI), donor-specific antibodies (DSAs)-negative and C4d-negative, was recently defined as a distinct phenotype by Banff 2022 and has been associated with adverse clinical outcomes. We have developed a model for rejection-related molecular classification of renal allograft biopsies using gene expression profiling of formalin-fixed paraffin-embedded renal biopsy tissue and evaluated its performance in patients with MVI. METHODS: Using this updated gene expression profiling-based multiclass model, we evaluated 138 biopsy specimens obtained from a large US transplant center, which included 42 biopsies diagnosed as MVI, DSA-negative, and C4d-negative. Clinical outcomes of patients in this MVI biopsy group were analyzed in relation to their molecular classifications. RESULTS: The molecular rejection classifications exhibited robust concordance with histology diagnoses of no rejection, antibody-mediated rejection, and T-cell-mediated rejection in this independent cohort, with concordance rates varying in each group from 85% to 93%. The molecular classification also showed a significant association with differential renal function and graft survival in the MVI, DSA-negative, and C4d-negative group. CONCLUSIONS: Our model demonstrates significant molecular differentiation among antibody-mediated rejection, T-cell-mediated rejection, and no rejection. In addition, our model classified MVI, DSA-negative, and C4d-negative samples into molecular subgroups associated with divergent clinical outcomes.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Molecular Classification Predicts Clinical Outcomes of Kidney Transplant Recipients With Microvascular Inflammation, Donor-specific Antibodies-negative and C4d-negative
- Date Crossref
- 23/07/2026
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Wisconsin–Madison pays non établi dans la noticeUniversité ou école supérieure
-
PAX Scientific (United States) pays non établi dans la noticeEntreprise
-
Inc. (United States) CareDx pays non établi dans la noticeEntreprise
-
Arkana Laboratories pays non établi dans la noticeStructure de recherche
-
Maine Medical Center Department of Medicine pays non établi dans la noticeÉtablissement de santé
-
School of Medicine and Public Health Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Clinical Biomarkers Center pays non établi dans la noticeÉtablissement de santé
University of Wisconsin–Madison, PAX Scientific (United States) et CareDx — Inc. (United States), avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.